Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 14;36(6):1625–1634. doi: 10.1038/s41375-022-01559-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — A Flow cytometry was used to assess CD4 and CD8 percentages in CAR-T cultures as shown. Data shown are sorted CAR + cells B Kaplan–Meier Survival of mice treated with CD19-CAR-T (n = 4), BCMA CAR-T (n = 8, 4 were tumor free and censored due to infection at housing facility), ΔCS1-BCMA-CAR-T (n = 9, 3 were tumor free and censored due to infection at housing facility) or left untreated (n = 2). C Bioluminescent imaging. Each line represents one mouse. D Flow cytometry was used to assess CD4 and CD8 percentages in CAR-T cultures as shown that were designed to have a high CD4:CD8 ratio. Data shown are sorted CAR + cells. E Survival and (F) BLI of mice treated with Luc90-CAR-T (n = 10), ΔCS1 Luc90-CAR-T (n = 10), CD79B CAR-T (n = 3) and untreated mice (n = 2). G Flow cytometry showing CD4 and CD8 percentages of CAR-T as shown generated to have a lower CD4:CD8 ratio. H Survival and (I) tumor burden (BLI) in mice treated with Luc90-CAR-T (n = 10), ΔCS1 Luc90-CAR-T (n = 10), CD79B CAR-T (n = 3) and untreated mice (n = 2). Although graphed separately, survival plots show same control mice (CD79B and untreated) since experiment was performed at same time.